Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis-Reference-Cited by-同舟云学术

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis

Published:2019-01 Issue:1 Volume:6 Page:e20-e28
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Dawwas Ghadeer K,Brown Joshua,Dietrich Eric,Park Haesuk

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Pulmonary embolism and deep vein thrombosis;Goldhaber;Lancet,2012

2. Heart disease and stroke statistics—2010 update: a report from the American Heart Association;Lloyd-Jones;Circulation,2010

3. Rivaroxaban or aspirin for extended treatment of venous thromboembolism;Weitz;N Engl J Med,2017

4. DOACs—advances and limitations in real world;Lee;Thromb J,2016

5. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism—a Danish nationwide cohort study;Sindet-Pedersen;Sci Rep,2017

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution;Mayo Clinic Proceedings: Innovations, Quality & Outcomes;2024-08

2. Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis;Nature Communications;2024-07-05

3. Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin;Research and Practice in Thrombosis and Haemostasis;2024-01

4. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study;Drug Safety;2023-12-23

5. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies;Journal of Thrombosis and Thrombolysis;2023-12-21